Democritus University of Thrace (DUTH)
Η μελέτη της επίδρασης του ανταγωνιστή της αλδοστερόνης, επλερενόνη, στην πρόγνωση ασθενών μετά από οξύ έμφραγμα του μυοκαρδίου και διατηρημένη συστολική λειτουργία της αριστεράς κοιλίας, με κριτήριο τον προσδιορισμό των επιπέδων ορού της μεταλλοπρωτεϊνάσης-9
Abstract
dc:descriptionObjectives We sought to assess possible interactions between eplerenone use and a plasma marker of collagen turnover on prognosis in post-myocardial infarction (MI) patients with preserved left ventricular (LV) ejection fraction (≥40%).Background In post-MI patients with systolic LV dysfunction eplerenone may improve survival. The beneficial effect of eplerenone on prognosis may be mediated through eplerenone’s effect on cardiac fibrosis. Methods 303 patients with acute MI (58±11 years, 249 male) and preserved systolic LV function were studied prospectively for 24 months. Plasma levels of matrix metalloproteinase-9 (MMP-9) were assessed on 7th day post-MI. Patients were divided into groups according to whether (n=201) or not (n=102) they received eplerenone (25 mg daily) as well as to their baseline MMP-9 levels using as a cut-off the one suggested by ROC curve analysis (12.7 ng/mL). The combination of death from cardiovascular causes, new non-fatal recurrent MI, hospitalisation for unstable angina and development of heart failure symptoms were considered as study end-points. Results Event-free survival was significantly lower among patients with low baseline MMP-9 levels compared to high baseline levels (56% vs. 76%, p<0.001). Eplerenone use was not associated with better prognosis in the whole study group (p=0.132). A beneficial eplerenone effect on outcome was significant only in patients with low baseline levels of MMP-9 (eplerenone (n=69): 65% vs. non eplerenone arm (n=33) 35%, p=0.005) Eplerenone had no effect (p=0.741) in the subgroup of patients with high MMP-9 baseline levels. Conclusions In post-MI patients with preserved LV systolic function, low baseline levels of MMP-9 are significantly associated with poor outcome and also identify a sub-group of patients in whom eplerenone use is associated with a survival benefit.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kampouridis, Nikolaos
- Καμπουρίδης, Νικόλαος
Subjects
dc:subject × 14- Επλερενόνη
- Έμφραγμα του μυοκαρδίου
- Διατηρημένη συστολική λειτουργία
- Αναδιαμόρφωση της αριστεράς κοιλίας
- Μεταλλοπρωτεϊνάση-9
- Eplerenone
- Myocardial infarction
- preserved systolic function
- Left ventricular remodelling
- Metalloproteinase-9
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/34918